Taken together, tumour antigen-specific CD8+ iTSCM cells are more likely to have potent antitumour effects, and the combination with the CD4+ iTSCM cells and the CD8+ iTSCM cells are thought to provide the strongest antitumour effects. This evidence concerns the gene CD8A and neoplasm.